Hostname: page-component-6bb9c88b65-zjgpb Total loading time: 0 Render date: 2025-07-24T21:59:07.489Z Has data issue: false hasContentIssue false
  • English
  • Français

Usage of oral vancomycin for acute Clostridioides difficile infection (CDI) resulting in later acquisitions of vancomycin-resistant enterococci (VRE)

Published online by Cambridge University Press:  16 May 2025

Evgeny Rogozin Open the ORCID record for Evgeny Rogozin [Opens in a new window] ,
Husam Maree ,
Majdi Masarwi Open the ORCID record for Majdi Masarwi [Opens in a new window] ,
Rozan Hasona ,
Herschel T. Horowitz ,
Ruth Bouganim  and
Dror Marchaim Open the ORCID record for Dror Marchaim [Opens in a new window]
Evgeny Rogozin
Affiliation:
Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel
Husam Maree
Affiliation:
Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel
Majdi Masarwi
Affiliation:
Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel
Rozan Hasona
Affiliation:
Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel
Herschel T. Horowitz
Affiliation:
Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
Ruth Bouganim
Affiliation:
Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
Dror Marchaim*
Affiliation:
Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
*
Corresponding author: Dror Marchaim; Email: drormarchaim@shamir.gov.il.
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Therapeutic guidelines for Clostridioides difficile infections (CDI) were revised a few years ago, promoting the usage of oral vancomycin even for primary mild infections. Vancomycin-resistant enterococci (VRE) is one of the worldwide most significant pathogens. Our study aim was to explore the independent association between oral vancomycin treatment for CDI, and subsequent VRE acquisitions.

Design:

Retrospective cohort study.

Setting:

Academic 904-bed general hospital (Shamir Medical Center, Israel).

Patients:

Adult (>18 yr) inpatients with primary CDI and no prior VRE.

Methods:

Study was conducted for calendar years 2016-2020. Logistic regression was used to model-independent predictors for VRE acquisitions. A propensity score (PS)-matched analysis (logistic regression) of the risk of receiving oral vancomycin was conducted to further eliminate potential confounders.

Results:

Overall, 606 patients were included (54% females), with a median age of 75 (IQR = 65–85) years. Independent predictors for VRE acquisition were oral vancomycin as a main therapy (aOR = 4.3, P < 0.001), exposure to systemic vancomycin in the previous 3 months (aOR = 3.2, P < 0.001), dependent functional status (aOR = 2.3, P = 0.006), and diabetes (aOR = 1.8, P = 0.04). After controlling for the PS, the independent association between oral vancomycin and later VRE acquisition remained significant in the regression model (aOR = 3.6, P < 0.01) and per PS matched-pairs analysis (aOR = 4.4, P < 0.01).

Conclusion:

Oral vancomycin administered for CDI had a strong independent association with later VRE acquisitions. This finding could promote stewardship interventions in an effort to reduce the usage of oral vancomycin for certain CDI indications, leading to improved CDI management, while curbing the continued emergence of VRE at hospitals.

Information

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 46 , Issue 7 , July 2025 , pp. 703 - 709
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Liu, C, Monaghan, T, Yadegar, A, Louie, T, Kao, D. Insights into the evolving epidemiology of Clostridioides difficile infection and treatment: a global perspective. Antibiotics (Basel). 2023;12:1141.CrossRefGoogle ScholarPubMed
Yakob, L, Riley, TV, Paterson, DL, et al. Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Sci Rep 2015;5:12666.CrossRefGoogle ScholarPubMed
Stevens, VW, Nelson, RE, Schwab-Daugherty, EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med 2017;177:546–553.CrossRefGoogle ScholarPubMed
Daneman, N, Cheng, Y, Gomes, T, et al. Metronidazole-associated neurologic events: a nested case-control study. Clin Infect Dis 2021;72:2095–2100.CrossRefGoogle ScholarPubMed
McDonald, LC, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–e48.CrossRefGoogle Scholar
van Prehn, J, Reigadas, E, Vogelzang, EH, et al. European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021;27:S1–S21.CrossRefGoogle ScholarPubMed
Dubberke, ER, Puckett, JT, Obi, EN, et al. Impact of updated clinical practice guidelines on outpatient treatment for Clostridioides difficile infection and associated clinical outcomes. Open Forum Infect Dis 2022;9:ofac435.CrossRefGoogle ScholarPubMed
Fishbein, SRS, Hink, T, Reske, KA, et al. Randomized controlled trial of oral vancomycin treatment in Clostridioides difficile-colonized patients. mSphere 2021;6:e00936-20.CrossRefGoogle ScholarPubMed
Tomas, ME, Mana, TSC, Wilson, BM, et al. Tapering courses of oral vancomycin induce persistent disruption of the microbiota that provide colonization resistance to Clostridium difficile and vancomycin-resistant enterococci in mice. Antimicrob Agents Chemother 2018;62:e02237-17.CrossRefGoogle ScholarPubMed
WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Healthimportance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Geneva: World Health Organization; 2024:72.Google Scholar
Miller, M, Bernard, L, Thompson, M, Grima, D, Pepin, J. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2010;31:710–715.CrossRefGoogle ScholarPubMed
Stevens, VW, Khader, K, Echevarria, K, et al. Use of oral vancomycin for Clostridioides difficile infection and the risk of vancomycin-resistant enterococci. Clin Infect Dis 2020;71:645–651.CrossRefGoogle ScholarPubMed
Zilberman-Itskovich, S, Youngster, I, Lazarovitch, T, et al. Potential impact of removing metronidazole from treatment armamentarium of mild acute Clostridioides difficile infection. Future Microbiol 2019;14:1489–1495.CrossRefGoogle ScholarPubMed
Lewis II, JS. CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition. CLSI; 2024:418.Google Scholar
Crobach, MJT, Planche, T, Eckert, C, et al. European society of clinical microbiology and infectious diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016;22:S63–81.CrossRefGoogle ScholarPubMed
Guidance for laboratory diagnostic of Clostridium difficile infection. Israeli Ministry of Health website. https://www.gov.il/BlobFolder/policy/bz12-2012/he/files_circulars_bz_BZ12_2012.pdf. Published 2012. Accessed March 13, 2025Google Scholar
Zar, FA, Bakkanagari, SR, Moorthi, KMLST, Davis, MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–307.CrossRefGoogle ScholarPubMed
Horn, SD, Sharkey, PD, Bertram, DA. Measuring severity of illness: homogeneous case mix groups. Med Care 1983;21:14–30.CrossRefGoogle ScholarPubMed
Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.CrossRefGoogle ScholarPubMed
Mitchell, BG, Dancer, SJ, Anderson, M, Dehn, E. Risk of organism acquisition from prior room occupants: a systematic review and meta-analysis. J Hosp Infect 2015;91:211–217.CrossRefGoogle ScholarPubMed
Katz, S, Ford, AB, Moskowitz, RW, Jackson, BA, Jaffe, MW. Studies of illness in the aged. the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–919.CrossRefGoogle Scholar
Sigakis, MJG, Posluszny, J, Maile, MD, Jewell, ES, Engoren, M. Is there an association between colonisation of vancomycin resistant Enterococci, methicillin resistant Staphylococcus Aureus, or Clostridiodes Difficile and mortality in sepsis? Infect Prev Pract 2024;6:100413.CrossRefGoogle ScholarPubMed
Fujitani, S, George, WL, Morgan, MA, Nichols, S, Murthy, AR. Implications for vancomycin-resistant enterococcus colonization associated with Clostridium difficile infections. Am J Infect Control 2011;39:188–193.CrossRefGoogle ScholarPubMed